Skip to site menu Skip to page content

Daily Newsletter

17 August 2023

Daily Newsletter

17 August 2023

DocGo and EmblemHealth join forces on in-home healthcare services

The collaboration aims to deliver in-home healthcare services to patients in New York and Connecticut.

August 16 2023

Mobile health services provider DocGo has partnered with EmblemHealth, a not-for-profit health insurer serving about three million individuals in New York City and the tri-state area.

The collaboration aims to deliver in-home healthcare services to patients in New York and Connecticut, particularly after hospitalisation, to bridge gaps in preventive healthcare.

Through this programme, DocGo will offer in-home health services to EmblemHealth's members, focusing on value-based care.

This initiative is expected to reduce costs and minimise hospital readmissions.

Services offered through this partnership include transitional care management after hospital discharge, as well as various screenings and tests such as diabetic retinal eye exams, bone density tests, A1C screenings, blood pressure control support, and colorectal cancer screenings.

By providing these services at home, the programme aims to facilitate early disease detection and prevent unnecessary hospital admissions.

In addition to mobile health services, DocGo's care delivery platform includes remote patient monitoring and ambulance services.

EmblemHealth CEO Karen Ignagni said: “High quality, accessible health care, remains out of reach for large segments of the population.

“By working with DocGo to offer post-acute care and critical screenings at home, our efforts to reduce health care disparities and improve health equity will be strengthened.

“We will make it easier for our members to get the preventive care they need, help them stay out of the hospital, optimise their long-term health and wellness, and help fulfil our mission of creating healthier futures for the communities we serve.”

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close